Language

English

Publication Date

4-2-2026

Journal

Vaccine

DOI

10.1016/j.vaccine.2026.128358

PMID

41740461

PMCID

PMC13222540

PubMedCentral® Posted Date

6-1-2026

PubMedCentral® Full Text Version

Author MSS

Abstract

Background: GRT-R910 (Gritstone bio, Inc), a self-amplifying mRNA vaccine expressing SARS CoV-2 (D614G) spike protein and T-cell epitopes, was evaluated as a booster vaccine in a phase 1 study in 2021-2022.

Methods: This open-label, dose escalation study enrolled healthy adults ≥112 days after completion of primary COVID-19 vaccination, booster of approved mRNA COVID-19 vaccine, or known SARS-CoV-2 infection. Persons aged 18-60 years received single doses of 3 or 6 μg GRT-R910 (n = 10/group). Persons >60 years of age received GRT-R910 at 3, 6, or 10 μg (n = 8-10/group). Safety and immunogenicity responses were assessed for 1 year after vaccination.

Results: We enrolled 48 participants. Most participants developed mild-to-moderate systemic reactions and/or injection site tenderness. Eight of 48 (17%) had severe systemic reactions. Pseudovirus neutralizing antibody geometric mean fold rise (GMFR) responses against SARS-CoV-2 (D614G) at Day 29 and Day 181, respectively, among those ≤60 years were 5.2 (95% CI 2.1, 13.3) and 6.1 (2.8, 13.2) after 3 μg, and 3.6 (1.3, 10.4) and 2.4 (0.2, 33.0) after 6 μg. The GMFR responses among those aged >60 years were 8.1 (2.1, 31.4) and 8.2 (1.2, 57.5) after 3 μg, 2.7 (1.1, 6.7) and 1.8 (0.5, 6.7) after 6 μg, 3.3 (1.5, 7.4) and 3.3 (1.3, 8.0) after 10 μg. The 6 μg dose group in those ≤60 years, 6 μg and 10 μg dose groups in those aged >60 years had higher baseline geometric mean titers (GMTs), which, in turn may have lowered the GMFR for those groups. GMFR persistence until Day 181 in most groups indicated these boosts were associated with durable increases in GMFR. Neutralizing antibody titers assessed via focus reduction neutralization test against SARS-CoV-2 D614G largely mirrored the PsVNA findings.

Conclusions: GRT-R910 was safe but reactogenic when administered to previously vaccinated or infected adults and boosted anti-SARS-CoV-2 neutralizing antibody responses in most participants with responses that appeared durable for up to 6 months.

Keywords

Adolescent, Adult, Female, Humans, Male, Middle Aged, Young Adult, Antibodies, Neutralizing, Antibodies, Viral, COVID-19, COVID-19 Vaccines, Epitopes, T-Lymphocyte, Immunization, Secondary, Immunogenicity, Vaccine, mRNA Vaccines, SARS-CoV-2, Spike Glycoprotein, Coronavirus, Vaccines, Synthetic, COVID-19, Vaccine, Self-amplifying, mRNA, GRT-R10

Comments

Clinical trial registration: https://clinicaltrials.gov/study/NCT04776317.

Clinicaltrials: gov ID NCT04776317.

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.